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Abstract
Context/Objective: Epidemiological studies have demonstrated that women have a significantly better prognosis in chronic
renal diseases compared to men. This suggests critical influences of gender hormones on glomerular structure and function.
We examined potential direct protective effects of estradiol on podocytes.
Methods: Expression of estrogen receptor alpha (ERa) was examined in podocytes in vitro and in vivo. Receptor localization
was shown using Western blot of separated nuclear and cytoplasmatic protein fractions. Podocytes were treated with
Puromycin aminonucleoside (PAN, apoptosis induction), estradiol, or both in combination. Apoptotic cells were detected
with Hoechst nuclear staining and Annexin-FITC flow cytometry. To visualize mitochondrial membrane potential
depolarization as an indicator for apoptosis, cells were stained with tetramethyl rhodamine methylester (TMRM).
Estradiol-induced phosphorylation of ERK1/2 and p38 MAPK was examined by Western blot. Glomeruli of ERa knock-out
mice and wild-type controls were analysed by histomorphometry and immunohistochemistry.
Results: ERa was consistently expressed in human and murine podocytes. Estradiol stimulated ERa protein expression,
reduced PAN-induced apoptosis in vitro by 26.5624.6% or 56.665.9% (flow cytometry or Hoechst-staining, respectively;
both p,0.05), and restored PAN-induced mitochondrial membrane potential depolarization. Estradiol enhanced ERK1/2
phosphorylation. In ERa knockout mice, podocyte number was reduced compared to controls (female/male: 80/86 vs. 132/
135 podocytes per glomerulus, p,0.05). Podocyte volume was enhanced in ERa knockout mice (female/male: 429/371 mm
3
vs. 264/223 mm
3 in controls, p,0.05). Tgfb1 and collagen type IV expression were increased in knockout mice, indicating
glomerular damage.
Conclusions: Podocytes express ERa, whose activation leads to a significant protection against experimentally induced
apoptosis. Possible underlying mechanisms include stabilization of mitochondrial membrane potential and activation of
MAPK signalling. Characteristic morphological changes indicating glomerulopathy in ERa knock-out mice support the in
vivo relevance of the ERa for podocyte viability and function. Thus, our findings provide a novel model for the protective
influence of female gender on chronic glomerular diseases.
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Introduction
Numerous epidemiological and animal studies demonstrated
that women have a significantly better renal outcome in chronic
glomerular diseases compared to men [1,2,3,4]. During the
physiological aging process, glomerular filtration rate (GFR)
declines faster in males than in females between 20 and 50 years
of age [5].
Lifestyle factors such as nutrition, smoking, and cardiovascular
risk factors (e.g. arterial hypertension) were identified as being
critical for a better renal prognosis in women. Nevertheless, these
do not fully explain the gender differences seen in various kidney
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27457diseases, as several studies adjusted for these risk factors have
shown [3,6].
In animal models, renal function is influenced by gender. Aging
male rats spontaneously develop proteinuria and glomeruloscle-
rosis, whereas female animals are remarkably resistant to these
changes [7]. These sequelae are largely prevented by estrogen
treatment alone [8] or in combination with orchiectomy [9] in
males. Female ERa knockout (KO) mice develop albuminuria,
glomerular hypertrophy and glomerular sclerosis between 6 and 9
months of age [10,11], compensatory kidney hypertrophy is
reduced following unilateral nephrectomy [12]. In other experi-
mental models of renal damage, such as uninephrectomy and
ovarectomy of spontaneously hypertensive rats (SHRsp) or
Puromycin aminonucleoside (PAN)-induced nephrosis, estradiol
reduced the expression of different glomerular damage markers
[13,14].
Reduced podocyte number, e.g. by podocyte apoptosis, is
critical for the development of proteinuria, glomerulosclerosis and
progressive kidney failure [15,16]. Consequently, apoptosis is
regarded as one of the key factors in multiple glomerular diseases,
especially focal-segmental glomerulosclerosis (FSGS) [17]. In
different non-renal cell types, numerous articles have shown that
gender hormones, in particular estrogens, have direct influences
on apoptosis through the binding to estrogen receptors (ER) [18].
Cytoplasmic and nuclear ER induce transcriptional regulation of
genes encoding for mitochondrial proteins, which indicates a link
between ER signalling and intact mitochondrial function [19].
Non-classical actions via membrane-associated estrogen receptors
include activation of multiple cytoplasmic signalling pathways
[20]. These result in protein modification without any genomic
action (e.g. phosphorylation processes), and in indirect genomic
effects via downstream signalling cascades modifying gene
transcription. Activation of mitogen-activated protein kinase
(MAPK) pathway, for example, occurs within minutes of estrogen
administration [21]. It comprises three major families of
intracellular signalling molecules (extracellular signal-regulated
kinase (ERK1/2), p38 MAPK, and c-Jun N-terminal kinases) with
downstream effects on cell proliferation, differentiation, motility,
survival, and apoptosis [22].
Both types of signalling pathways – transcriptional regulation
via nuclear ER and regulation of phosphorylation cascades via
membranous and cytoplasmic ER – are able to protect cells
against apoptotic stimuli.
Regarding the crucial role of podocytes for chronic glomerular
diseases, we investigated expression of ERa on podocytes in-vitro
and in-vivo. Furthermore, we examined possible protective actions
of estradiol treatment on experimentally induced apoptosis in
cultured podocytes. One essential mechanism involved in
apoptosis is destabilization of mitochondrial function, which we
visualized by staining mitochondrial membrane potential.
Finally, we correlated the in-vivo findings with podocyte number
and morphology, and markers of glomerular damage in ERa
knockout mice compared to wild-type and heterozygous controls.
Results
ERa is expressed in cultured murine podocytes, mouse
and human kidney tissue
Immunocytochemical stainings of cultured murine podocytes
showed ERa protein with both cytoplasmic and nuclear staining
(Fig. 1A).
In wild-type mouse kidney, ERa protein was found in tubular
and glomerular cells, while expression was absent in ERa KO
mice (Fig. 1B). Immunohistochemical staining of human renal
biopsies showed glomerular expression of ERa (Fig. 1C).
Western blot analyses confirmed the presence of ERa protein in
murine podocytes (Fig. 2). In control cells without any residual
estrogenic influence, significant amount of receptor protein was
detected only in the nuclear protein fraction. After stimulation
with 10nM estradiol for 24h, ERa protein increased significantly
in the nucleus, but became also detectable in the cytoplasmic
protein fraction. Prolonged stimulation with estradiol for 48h
further increased the amount of ERa protein in the cytoplasm,
while nuclear protein remained unchanged.
Estradiol protects podocytes from apoptosis
PAN treatment of cultured murine podocytes led to a significant
induction of apoptosis. The amount of apoptosis in the puromycin-
treated group varied between 7.9% and 36.5% (FACS-analysis), or
18.6% and 27.3% (Hoechst-staining), respectively (Fig. 3). Varia-
tions within one experiment were negligible. Apoptosis after PAN
treatment was set to 100% in each experiment for normalization,
other treatment groups are given as a percentage relative to PAN-
treatment.
Analyzed by flow cytometry, estradiol treatment, which started
24 h prior to the start of incubation with PAN, induced a
significant reduction of apoptosis compared to PAN treatment
alone, namely by an average of 26.5624.6% (p=0.014, Fig. 3A).
Even more effective protection against PAN-induced damage was
achieved using dexamethasone, which was included as a positive
control (77624.2% average reduction in apoptosis compared to
PAN treatment alone, p=0.001).
Hoechst nuclear staining showed similar results: Combining PAN-
treatment with estradiol led to a 56.665.9% reduction of apoptosis
compared to PAN treatment alone (p,0.001, Fig. 3B). Dexameth-
asone reduced PAN-induced apoptosis by 90.165.3% (p=0.001).
Estradiol stabilizes mitochondrial membrane potential
PAN treatment induced a significant loss of TMRM staining
intensity within 48 hours (121.464.1 arbitrary units, control:
142.762.0 arbitrary units; p=0.026; Fig. 4). This finding indicates
a depolarization of mitochondrial membrane potential, an initial
step of the apoptotic process. Combination of PAN with estradiol
prevented the loss of mitochondrial membrane potential com-
pared to PAN treatment alone (146.163.9 vs. 121.464.1 arbitrary
units; p=0.026).
Estradiol induces anti-apoptotic MAPK signalling by
phosphorylation of ERK1/2
Estradiol extensively stimulated ERK1/2 phosphorylation,
beginning already 1 min after beginning of treatment (Fig. 5). In
contrast, we detected only very small stimulation of p38 MAPK
phosphorylation.
Reduced podocyte number, increased podocyte volume
and increased TGFb1 and collagen Type IV expression in
ERa knockout mice
Six-month old ERa knockout mice did not show any significant
differences compared to wild-type and heterozygous mice
regarding glomerular sclerosis index, number of glomeruli and
mean glomerular volume (Table 1). Total number of podocytes
was significantly reduced in male and female ERa knockout
animals compared to all wild-type and heterozygote animals
(Fig. 6A). Mean podocyte volume was significantly enhanced in
male and female ERa knockout mice compared to all other groups
(Fig. 6B). Mesangial cell number and volume showed the same
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PLoS ONE | www.plosone.org 2 November 2011 | Volume 6 | Issue 11 | e27457Figure 2. Western blot of ERa protein in cultured podocytes. In control cells without any residual estrogenic influence, the receptor protein
was detected only in nuclear protein fraction. After stimulation with 10 nM estradiol for 24 h, ERa protein increased significantly in the nucleus, but
was also detected in the cytoplasmatic protein fraction. Prolonged stimulation with estradiol for 48 h further increased the amount of ERa protein in
the cytoplasm, while nuclear protein remained unchanged.
doi:10.1371/journal.pone.0027457.g002
Figure 1. Expression of ERa in podocytes. A) Immunocytochemical staining of ERa (red) in cultured murine podocytes with cytoplasmatic and
nuclear localization. DAPI was used for nuclear staining (blue), negative control was performed without ERa primary antibody. B)
Immunohistochemical detection of ERa protein (red) in mouse kidney. ERa KO mice completely lack ERa expression in kidney tissue. C)
Immunohistochemical detection of ERa protein (red) in human kidney tissue. Breast tissue and heart tissue were used as positive and negative
controls, respectively.
doi:10.1371/journal.pone.0027457.g001
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isons (Fig. 6A and 6B).
Tgfb1 and Collagen type IV expression were increased in ERa
knockout animals compared to wild-type and heterozygous
controls (Fig. 6C and 6D).
Discussion
While clinical and epidemiological studies provide an increasing
body of evidence for substantial gender differences regarding the
progression of chronic glomerular diseases, this report demon-
strates a direct protective effect of estradiol on podocyte survival.
The consistent demonstration of ERa expression in cultured
murine podocytes and in podocytes of murine and human kidney
specimens underlines the biological relevance of ERa for kidney
physiology. In cultured podocytes, immunofluorescence staining
showed ERa protein with cytoplasmic and nuclear localization.
For these experiments, we used podocytes that were exposed to a
phenol red-containing medium and non-stripped FCS, explaining
Figure 3. Apoptosis quantification. A) FACS-analysis of apoptosis in murine podocytes. Combination of PAN with estradiol reduced apoptosis by
an average of 26.5% compared to PAN treatment alone (* p=0.014). Dexamethasone was used as a positive control. B) Hoechst nuclear staining for
the detection of apoptosis in murine cultured podocytes. Combination of PAN with estradiol reduced apoptosis by an average of 56.6% compared to
PAN treatment alone (* p,0.001).
doi:10.1371/journal.pone.0027457.g003
Figure 4. TMRM staining of mitochondrial membrane potential. A) TMRM staining shows reduced mean pixel intensity after PAN treatment,
indicating loss of mitochondrial membrane potential. This can be fully prevented by co-treatment with estradiol (*p=0.026). B) Representative
images of TMRM staining.
doi:10.1371/journal.pone.0027457.g004
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cytoplasmatic compartments.
For a more detailed analysis, control cells for Western blot were
cultured using phenol red-free medium and stripped FCS to
exclude any residual estrogenic influences. This led to an ERa
detection only in the nuclear compartment, while cytoplasmic
protein did not reveal significant ERa expression. After estradiol
stimulation, ERa was detected also in the cytoplasmic compart-
ment, and expression was extensively enhanced in the nuclear
compartment. Whether this is only due to an increased production
of ER or indicates further relocation processes between nucleus
and cytoplasm has not been addressed in detail.
Extensive studies are available for breast carcinoma cells, in
which ER relocation between nucleus, cytoplasm and cell
membrane was shown to be induced by estrogen, mediated by
the Src homologous and collagen (Shc) adapter protein [23],
which in turn associates with f-actin [24]. Interestingly, these
adapter proteins and relocation processes turned out to be critical
for many non-genomic estrogenic actions in breast-carcinoma
cells, such as activation of mitogen-activated protein kinase
(MAPK) and phosphoinositide 3-kinase (PI3-kinase) [25].
However, our results may point to similar interaction and
relocation processes also in podocytes. However, further analyses
are required to delineate the biological relevance of these findings.
As podocyte apoptosis represents one of the key mechanisms in
glomerular damage, we were especially interested in the effects of
estradiol on podocyte apoptosis. PAN treatment is the best-
established model of apoptosis induction in podocytes and is
regarded as a reliable experimental model for several glomerular
diseases [26]. While animals treated with a single dose of PAN
develop minimal-change disease-like transient proteinuria, repeat-
ed application results in persistent proteinuria and focal segmental
glomerulosclerosis (FSGS), mimicking FSGS in humans.
Applying this model in-vitro, we were able to show significant
prevention of PAN induced apoptosis by estradiol using two
different methods of apoptosis detection. In the FACS analysis, the
maximum percentage of apoptotic cells after PAN treatment
showed some variation between different experiments. This may
be explained by the high susceptibility of the method to even the
slightest variations in the experimental procedure. Enzymatic
detachment of cells from culture dishes, for example, is known to
induce Annexin-FITC positivity in cells. Nevertheless, the
reproducibility of the relative changes between treatment groups
as well as the good correlation with the results obtained by
Hoechst staining confirm the significance of our FACS results.
Our results are supported by recent data by Doublier et al., who
demonstrated that ER-mediated signalling protects podocytes
from Tgfb1 or TNFa-induced apoptosis, while testosterone
induced podocyte apoptosis by signalling via androgen receptors
[11].
Regarding the underlying mechanisms of estrogen action, we
analyzed the mitochondrial membrane potential in podocytes. It is
critical for the process of apoptosis via two distinct mechanisms.
First, opening of the mitochondrial permeability transition pore
(PTP) leads to the release of apoptogenic factors from the
intermembrane space into the cytosol (e.g. cytochrome c, apoptosis
inhibiting factor, Smac/Diablo). Second, changes of mitochondri-
al membrane potential cause disturbances in the process of
oxidative phosphorylation, leading to cellular damage by impaired
ATP/energy metabolism. These processes can occur either as an
initiation step towards apoptosis or as a consequence of the
apoptotic process, depending on the examined cellular system and
the mechanism of damage induction [27]. Adenine nucleosides,
such as PAN used in our experiments, disrupt mitochondrial PTP.
Thus, changes in the mitochondrial membrane potential represent
an early step of apoptosis in our experimental model.
In line with these assumptions, we demonstrate for the first time
a PAN induced destabilization of mitochondrial membrane
potential in podocytes. I was possible to reduce this effect by
pretreatment with estradiol and even more by dexamethasone.
Similar results were already investigated extensively in neurons
and other cells, where estrogens show cytoprotective effects by
interfering with mitochondrial function via nuclear and non-
nuclear signalling pathways [19,28].
Other possible mechanisms, such as activation of MAPK and
inositol-triphosphate-kinase (IP3K) phosphorylation by membra-
nous ER, were shown to have significant impacts on actin
cytoskeleton, cellular proliferation, apoptosis and movement. For
example, estrogen-induced activation of the Raf-MEK-ERK-
p90RSK cascade was already shown to mediate protection of
neurons against apoptosis via stabilization of Bad phosphorylation
[21]. In our study, we demonstrated intensive stimulation of
ERK1/2 phosphorylation induced by estradiol also in podocytes.
This may contribute to the anti-apoptotic effect of estradiol in
podocytes. Similar data supporting our hypothesis were obtained
very recently by Doublier et al., who demonstrated a reduced
antiapoptotic effect of estradiol in podocytes after ERK inhibition
[11]. In contrast, estradiol hardly increased p38 MAPK
phosphorylation, which is generally regarded as ‘‘stress-activated’’
kinase, promoting inflammation and apoptosis [29]. These
findings underline the importance of non-genomic signalling for
anti-apoptotic action of estradiol in podocytes.
It is noteworthy, that all our experiments analysing estrogen
effects were performed with cell culture medium containing
physiologic doses of estradiol before induction of apoptosis by
PAN. Therefore, our results primarily focus on estrogenic
influences on the prevention of injury and on the modification
of the disease course. Further studies will have to address the
possible therapeutic actions of estrogen for established renal injury
using pharmacological doses of estradiol after induction of
experimental damage. In addition, cyclic variation of estrogen
concentration, as occurring in-vivo, may lead to different results.
To evaluate the in-vivo relevance of our data, we compared
glomerular structures of ERa knockout mice to those of wild-type
Figure 5. MAPK phosphorylation after estrogen treatment.
Estradiol extensively stimulated ERK1/2 phosphorylation, beginning
already 1 min after beginning of treatment (Fig. 5). In contrast, we
detected only very small stimulation of p38 MAPK phosphorylation.
doi:10.1371/journal.pone.0027457.g005
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type, Hetero = heterozygote, KO = knockout; n=6 animals per group).
Number of glomeruli (left kidney) Mean glomerular volume [10
6 mm
3] Glomerular sclerosis index
femaleWT 2214264318 0.5460.19 0.7560.69
maleWT 2500466986 0.3360.12 0.8760.37
femaleHetero 2178867458 0.3760.17 1.3160.33
maleHetero 2049967988 0.5060.25 0.9860.46
femaleKO 2269464454 0.3560.11 0.9860.13
maleKO 2027864555 0.3460.07 0.9760.50
ANOVA p=0.798 (n.s.) p=0.113 (n.s.) p=0.433 (n.s.)
doi:10.1371/journal.pone.0027457.t001
Figure 6. Glomerular cells and matrix in ERa knockout mice. Compared to heterozygeous and wild-type animals, podocyte numbers were
significantly reduced (A) and podocyte volume significantly increased (B) in ERa knockout animals. Mesangial cell number and volume showed the
same tendencies, but reached significance only in some of the intergroup comparisons (A, B). Tgfb1 and Collagen type IV expression is increased in
KO animals (C, D). n=6 animals per treatment group.
a p,0.05 vs. femaleWT,
b p,0.05 vs. maleWT,
c p,0.05 vs. femaleHetero,
d p,0.05 vs.
maleHetero,
e p,0.05 vs. femaleKO,
f p,0.05 vs. maleKO. ANOVA with Tamhane post-hoc analysis (p,0.01).
doi:10.1371/journal.pone.0027457.g006
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fewer, but bigger than in heterozygous and wild-type controls.
Both findings – loss of podocyte number and cellular hypertrophy
- indicate podocyte injury in ERa knockout animals.
Upregulation of Tgfb1 and Tgfb1-mediated collagen type IV
expression in glomeruli of ERa knockout mice complemented the
evidence of podocyte damage. Tgfb1-expression is known to be
associated with podocyte damage by the stimulation of extracel-
lular matrix accumulation [30], while estrogen supplementation
was shown to prevent Tgfb1 mediated glomerulopathy [31]. The
glomerular sclerosis index, another unspecific indicator of
structural glomerular damage, also shows a trend towards
increased sclerosis in knockout animals, but did not reach
statistical significance after correcting with Tamhane’s post-hoc
analysis.
In ERa knock-out mice, proteinuria was shown to develop
between 6 and 9 months of age [10]. To demonstrate early
processes of podocyte damage before a more global glomerular
damage and overt proteinuria has developed, we used 6 month-old
mice and did not apply any further experimental renal damage. In
contrast to other groups [10,12,32], we were able to demonstrate
deleterious effects of ERa knockout not only in female but also in
male animals. [10,12,32]. Thus, ERa-mediated signalling is
critical in mice of both genders for maintaining healthy kidney
function.
Whether the renal damage in ERa knockout animals is caused
by the lack of podocyte ERa expression or by secondary effects
due to the unspecific knockout of ERa throughout the body
remains to be shown. The unselective ERa knockout leads to
increased estrogen and luteinizing hormone (LH) levels via
decreased negative feedback mechanisms through the hypotha-
lamic-pituitary-gonadal axis [33]. The increased LH level induces
17beta-hydroxysteroid dehydrogenase type III activity in ovaries
of ERa knockout mice, stimulating ovarian production of
testosterone that further compromises renal outcome [10,33].
Whereas our in-vivo data may also be explained by these
secondary effects, our in-vitro data as well as recent data from
other groups [11] support a protective role for the ERa
expression in podocytes.
Interactions between gender hormones and kidney structure
and function are probably even more complex. Although for
cytoprotective action ERa seems to be of major interest [34],
podocytes also express ERb and androgen receptors [11].
Consequently, interactions between gender and podocyte biology
may be based on an interplay between androgenic and estrogenic
hormones, influencing a branched signalling network with various
downstream effects, e.g. on proliferation, apoptosis, cytoskeleton
and movement.
Finally, our data raise the question of a therapeutic applicability
of estrogens for chronic glomerular diseases. There is one
anecdotal report published in 1955, in which estrogens were used
for the therapy of three patients (two women and one man) with
nephrotic syndrome [35]. Initially, all three had complete
remission of proteinuria, but unfortunately relapsed after the
discontinuation of the therapy. The two women immediately
received an additional course of hormones and again achieved
remission, while the man could not be convinced to take more
estrogens due to the significant side effects and sadly died in a
nephrotic crisis.
The potential therapeutic use of estrogens for renal diseases has
to be regarded with caution as hormone replacement therapy may
be associated with increased risk of breast cancer and cardiovas-
cular diseases [36]. Short-term side effects, such as feminization,
may have substantial impact on the compliance of male patients.
Furthermore, postmenopausal hormone replacement therapy
(HRT) in women and experimental high-dose estrogen adminis-
tration in mice have been shown to be associated with renal
damage [37,38]. Others demonstrate an improved renal prognosis
for women under HRT [39]. However, selective estrogen receptor
modulators (SERM) with tissue specific effects and less feminizing
potential may provide a reasonable new option for patients with
chronic glomerular diseases.
In conclusion, podocytes contain ERa which upon activation
mitigates experimentally induced apoptosis in-vitro. The early
stage of glomerulopathy in ERa knockout mice is characterized by
a reduced number of podocytes and morphological changes,
which are in line with an in-vivo relevance of ER for podocyte
viability and function. Thus, our findings provide a novel model
explaining protective influences of female gender on the outcome
of chronic glomerular diseases in humans.
Materials and Methods
Cell culture
Immortalized murine podocytes were a generous gift of Peter
Mundel (University of Miami, USA) and cultured as described
previously [40]. Cells for analyzing estrogen influences were
maintained in charcoal-stripped fetal bovine serum (FB-1001F/
500, Biosera, East Sussex, UK) and phenol-red free culture
medium (E15-848, PAA, Pasching, Austria) for at least 6 days
before starting the experiments to exclude residual estrogenic
action of culture medium.
Differentiation of cells was confirmed by ensuring arborized
morphology and expression of Synaptopodin and Wt1 with real-time
PCR and Synaptopodin by immunocytochemistry (results not
shown).
Immunocytochemical/Immunohistochemical detection
of ERa
For immunofluorescence, cells were grown on glass coverslips.
After 14d of differentiation cells were fixed with PBS/4%
paraformaldehyde and permeabilized with PBS/0.5% Triton X-
100/3% BSA.
ER protein was visualized by indirect immunofluorescence
using ERa antibody (C1355, Millipore, Schwalbach, Germany)
at 1:500 dilution for 12 h at 4uC, and chicken anti-rabbit
secondary antibody coupled to Alexa fluor 594 (Molecular
Probes, Oregon, USA) at 1:1000 dilution for 60min at room
temperature. All cells were co-stained with 4,6-diamidino-2-
phenylindole dihydrochloride (DAPI, 1 mg/mL) for visualisation
of cell nuclei. Coverslips were mounted on microscope slides;
images were acquired with Nikon Eclipse Ti inverted fluorescence
microscope and NIS Elements AR 3.1 software (Nikon, Duesseldorf,
Germany) using a 20x objective lens. Negative controls were done
without ERa primary antibody.
ERa staining of human kidney biopsy specimen was performed
during routine histopathologic examination as described previ-
ously [41]. Breast and heart tissue specimens were used as positive
and negative controls, respectively.
ERa staining of murine kidney tissue was carried out on paraffin
sections using ERa antibody (sc-7207, Santa Cruz, Santa Cruz,
USA) in 1:25 dilution for 1 h at room temperature, followed by
3% H2O2 for 7 min. Primary antibody was detected using the
Histofine Simple Stain MAX-PO (Multi) kit (Nichirei Co, Tokyo,
Japan) and AEC substrate (DAKO, Hamburg, Germany) for
10 min. Color development was stopped by adding Aqua dest,
finally sections were counterstained with hematoxylin.
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ERa Western blot
Cells were grown as described above, using phenol-red free
medium and stripped FCS for at least 6 days before beginning of
experiments. After 12 d of differentiation, cells were starved for
24 h with FCS concentration reduced to 1%. Cells dedicated for
estrogen treatment were exposed to a medium containing 10 nM
1,3,5-Estratriene-3,17ß-diol (estradiol, E2758, Sigma-Aldrich,
Munich, Germany), and controls were maintained in estrogen-
free culture medium. Cells were detached after 24 h or 48 h,
respectively, using Alfazyme (L11-012, PAA) for 5 min in 37uC.
Afterwards, cells were pelleted and put on ice. Nuclear-
cytoplasmic fractionation and protein extraction were conducted
using the NE-PER Nuclear and Cytoplasmic Extraction Reagents kit
(Thermo Scientific, Rockford, USA) according to the manufac-
turer’s protocol.
For Western blot, 4x NuPAGE LDS Sample Buffer (Invitrogen,
Darmstadt, Germany) was added to protein samples and boiled for
5 min at 72uC. Proteins were separated using NuPAGE Novex 12%
Bis-Tris Gel (Invitrogen) and transferred on Immobilon-P PVDF
membrane (Millipore) using a XCell SureLock Mini-Cell electrophoresis
and blotting system (Invitrogen). SeeBlue Plus2 prestained Standard
(Invitrogen) was used as a protein marker.
The membrane was blocked in 5% milk for 1h at room
temperature and incubated overnight at 4uC with ERa antibody
(ab2746, Abcam, Cambridge, UK), diluted 1:1000 in Super Block
Blocking Buffer (Thermo Scientific). After washing with PBS and
incubation with horseradish peroxidase-conjugated anti-mouse
IgG (JL315035044, Jackson Immuno Research, Suffolk, UK),
detection was performed by the Super Signal West Pico Chemilumi-
nescent substrate (34080, Thermo Scientific) and visualized by Fujifilm
Super-RX Film (47410 08389, Fujifilm, Duesseldorf, Germany).
Film was processed using Curix 60 film processor (AGFA,
Greenville, USA) and scanned with a Canon SmartBase MPC600F
scanner (Canon, Krefeld, Germany).
For differentiation between protein fractions, anti-GAPDH
antibody (sc-48166, Santa Cruz, Santa Cruz, USA) was used as
marker for cytoplasmatic fraction, diluted 1:3000 in Super Block
Blocking Buffer (Thermo Scientific) and incubated overnight at 4uC.
The nuclear fraction was detected by anti-Phospho-Histone H3
antibody (#9714, Cell Signaling, Danvers, USA; diluted 1:1000 in
Super Block Blocking Buffer, and incubated overnight at 4uC).
Apoptosis induction and detection in cultured podocytes
After 14d of differentiation, cells dedicated for estradiol
treatment were pretreated by culture medium with 10 nM
estradiol for 24 h. Control groups were exposed to medium
change only. Apoptosis was induced by a medium with 30 mg/ml
Puromycin aminonucleoside (PAN, P7130, Sigma-Aldrich) for 48h
in the presence or absence of estradiol. As positive control, cells
were treated with 1 mM (11b,16a)-9-Fluoro-11,17,21-trihydroxy-
16-methylpregna-1,4-diene-3,20-dione (dexamethasone, D4902,
Sigma-Aldrich) in the same time-intervals and treatment groups
as estradiol. Apoptosis was quantified by the following methods:
Hoechst 33342 Staining: After collecting supernatant medium with
detached cells, cultures were washed with PBS and detached using
Alphazyme (L11-012, PAA) for 8 min at 37uC, pelleted for 5 min
by centrifugation at 1100 rpm, washed with PBS, resuspended in
2.5 ml native medium and incubated for 1h at 37uC. After that,
Hoechst 33342 (14533, Sigma-Aldrich) was added to the medium to
a final concentration of 1 mM/ml for 15 min at 37uC. Cells were
fixed for 15min at room temperature with 4% formalin (6459124,
Fischar, Saarbruecken, Germany). After pelleting, cells were
resuspended in 100 ml PBS, dispensed on a microscope slide and
dried for 1h in the dark. Slides were covered by Prolong Gold Antifade
reagent (P36930, Invitrogen) and coverslips. Cells were visualized by
an Axiovert 200M fluorescence microscope (Zeiss, Oberkochen,
Germany). Apoptosis was defined as the percentage of cells
showing nuclear condensation/fragmentation in at least 300
consecutive cells.
Flow cytometry: Apoptosis was assessed using Annexin V-FITC kit
(PN IM3546, Beckman Coulter, Krefeld, Germany). Cells were
harvested from culture flasks as described above. After 1h of
incubation in 10ml native culture medium, cells were pelleted and
resuspended in Annexin binding buffer. The following staining
protocol was performed according to the manufacturer. Staining
was detected on a FACSCalibur flow cytometer (Becton Dickinson,
Heidelberg, Germany). At least 10,000 cells per treatment
condition were analyzed on CellQuest Pro software (Becton
Dickinson, Heidelberg, Germany). Cells that were Annexin V
positive and propidium iodide negative were considered apoptotic.
TMRM-staining of mitochondrial membrane potential
After 14d of differentiation on glass coverslips, apoptosis was
induced with PAN (30 mg/ml) for 48h in the presence or absence
of 10 nM estradiol. After 48 h, podocytes were incubated in a
medium containing 100 nM tetramethyl rhodamine methyl ester
(TMRM; Invitrogen) for 25 min at 37uC, allowing mitochondria
to load with TMRM fluorescent dye in proportion to mitochon-
drial membrane potential. After washing with PBS, coverslips were
mounted in chambers containing HEPES-Tris buffer (pH 7.4,
prewarmed at 37uC). The chambers were mounted on an Axiovert
200M fluorescence microscope (Zeiss) equipped with a 63x/1.4 oil
immersion objective. Life-cell images were acquired using
Axiovision software. Further image processing and analysis were
performed using Image Pro software (Media Cybernetics, Silver
Spring, MD, USA) as described before in detail [42]. Staining
intensity is given in arbitrary units.
ERK1/2 and p38 MAPK Western Blot
Cells were grown as described above, using phenol-red free
medium and stripped FCS for at least 6 days before beginning of
experiments. After 12d of differentiation, cells were starved for
24 h with FCS concentration reduced to 1%. Cells dedicated for
estrogen treatment were exposed to medium containing 10nM
estradiol, controls were maintained in estrogen-free culture
medium.
Cells were harvested after 0, 1, and 5 minutes using Tissue Protein
Extraction buffer (#78510, Thermo Scientific) supplemented with
Complete Protease Inhibitor Cocktail (Roche, Indianapolis, USA),
incubated on ice for 10 min, centrifuged for 10 minutes at 4uC
and 16,000 g. Supernatant was collected and supplemented with
4x NuPAGE LDS Sample Buffer (Invitrogen). Lysates were boiled for 10
minutes at 72uC and loaded onto NuPAGE 4-12% Bis-Tris Gel
(Invitrogen). Protein separation, blotting and membrane blocking
were performed as described above.
Stainings were performed using anti-phospho ERK1/2 (#9101,
Cell Signaling, 1:1,000), anti-ERK1/2 (#9102, Cell Signaling,
1:1,000), anti phospho-p38 MAPK (#9215, Cell Signaling,
1:1,000) and anti-bActin antibodies (A5441, Sigma-Aldrich,
1:3,000), each diluted in Super Block Blocking Buffer (Thermo
Scientific) and incubated overnight at 4uC.
After washing, the membrane was incubated with horseradish
peroxidase-conjugated anti-rabbit IgG (JL711035152, Jackson
Immuno Research, 1:10,000; against phospho-ERK1/2, ERK1/
2, phospho-p38 MAPK) and anti-mouse IgG (JL315035044,
Jackson Immuno Research, 1:20,000; against b-Actin) for 1 hour
at room temperature.
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as described above.
ERa knockout mice
All animal experiments were approved by the Institutional
Animal Care and Use Committee of the University Hospital
Heidelberg (permit numbers AZ 35-9185.81/G-103/02 and AZ
35-9185.81/G-142/03) and conducted in accord with accepted
standards of humane animal care. All efforts were made to
minimize suffering.
We used ERa
-/- mice generated from C57BL/6 mice as
previously described by Dupont et al. [43], kindly provided by
Prof. Pierre Chambon (Strasbourg, France) and Dr. Theo Pelzer
(Wuerzburg, Germany). Mice were housed in box cages under
standard conditions and bred to yield homozygous (ERa
-/-),
heterozygous (ERa
+/-) and wild-type (ERa
+/+) animals. The
correct genotype was confirmed by PCR amplification of genomic
DNA extracted from tail tissue. All animals had free access to
water and chow (Altromin 1324, 1% NaCl, soy-free, low in
phytoestrogens; Altromin, Lage, Germany).
Six months old mice were allocated to the following
experimental groups: (1) wild-type females, (2) heterozygous
females, (3) homozygous knockout females, (4) wild-type males,
(5) heterozygous males, (6) homozygous knockout males; each
group contained n=6 animals.
Animals were sacrificed after anaesthesia with ketamine and
xylazine. After perfusion with NaCl 0,9%, right kidney was
harvested; 50% was frozen in liquid nitrogen, the remaining tissue
formaline-fixed for immunohistochemical staining.
Then the remaining animal was perfused with 3% phosphate-
buffered glutaric aldehyde before harvesting of the remaining
organs. The left kidney was sectioned in a plane perpendicular to
the interpolar axis, yielding slices of 1–2 mm width. Five
representative samples of renal cortex were cut using area
weighted sampling [44] with subsequent additional fixation with
glutaric aldehyde for 4 h, washing with PBS and another fixation
step in 1% osmium tetroxide for 1h. Semithin sections of 1 mm
were prepared and stained with periodic Schiff-acid for analysis of
glomerular sclerosis index/glomerular number or stained with
toluidine blue for analysis of podocyte/mesangial cell number and
cell volume.
The glomerular sclerosis index, indicating glomerular damage,
was calculated as described previously [45]. In five semithin
sections for each animal, the glomerular number and volume were
analyzed as described previously [46,47]. Glomerular cell numbers
and cell volumes (podocytes and mesangial cells) were calculated
as described previously in at least 30 glomeruli per animal [46,48].
Immunohistochemical stainings of Tgfb1 and Collagen type IV
were performed with paraffin sections as described previously [49],
using the following antibodies: anti-Tgfb1 (1:100 dilution for 1h at
room temperature; Santa Cruz), anti-Collagen type IV antibody
(1:100 dilution for 1h at room temperature; Biotrend, Cologne,
Germany). Stainings were analyzed by two blinded independent
investigators; scoring was performed semiquantitatively in 20
glomeruli per kidney as described elsewhere [46].
Statistical analysis
Results are given as mean 6SE. Statistical analysis was
performed using SPSS 18.0 software for Mac (SPSS Inc., Munich,
Germany) and one-way ANOVA with Tamhane post-hoc
analysis. Statistical significance was defined as p,0.05.
Author Contributions
Conceived and designed the experiments: SK SJ LVW AP PL AS NK MB
EM M-LG-W JO FM. Performed the experiments: SK SJ LVW AP PL AS
NK FM EH. Analyzed the data: AK SJ LVW AP PL AS NK M-LG-W JO.
Contributed reagents/materials/analysis tools: SK SJ LVW AP PL AS NK
EM M-LG-W JO. Wrote the paper: SK SJ LVW AP MB EM JO CPS.
References
1. Silbiger SR, Neugarten J (1995) The impact of gender on the progression of
chronic renal disease. Am J Kidney Dis 25: 515–533.
2. Neugarten J, Acharya A, Silbiger SR (2000) Effect of gender on the progression
of nondiabetic renal disease: a meta-analysis. J Am Soc Nephrol 11: 319–329.
3. Cattran DC, Reich HN, Beanlands HJ, Miller JA, Scholey JW, et al. (2008) The
impact of sex in primary glomerulonephritis. Nephrol Dial Transplant 23:
2247–2253.
4. Kummer S, von Gersdorff G, Kemper MJ, Oh J (2011) The influence of gender
and sexual hormones on incidence and outcome of chronic kidney disease.
Pediatric nephrology.
5. Berg UB (2006) Differences in decline in GFR with age between males and
females. Reference data on clearances of inulin and PAH in potential kidney
donors. Nephrol Dial Transplant 21: 2577–2582.
6. Silbiger SR, Neugarten J (2003) The role of gender in the progression of renal
disease. Adv Ren Replace Ther 10: 3–14.
7. Elema JD, Arends A (1975) Focal and segmental glomerular hyalinosis and
sclerosis in the rat. Lab Invest 33: 554–561.
8. Hajdu A, Rona G (1971) The protective effect of estrogens against spontaneous
pancratic islet and renal changes in aging male rats. Experientia 27: 956–957.
9. Gilboa N, Magro AM, Han Y, Rudofsky UH (1987) Contrasting effects of early
and late orchiectomy on hypertension and renal disease in fawn-hooded rats.
Life Sci 41: 1629–1634.
10. Elliot SJ, Berho M, Korach K, Doublier S, Lupia E, et al. (2007) Gender-specific
effects of endogenous testosterone: female alpha-estrogen receptor-deficient
C57Bl/6J mice develop glomerulosclerosis. Kidney Int 72: 464–472.
11. Doublier S, Lupia E, Catanuto P, Periera-Simon S, Xia X, et al. (2011)
Testosterone and 17beta-estradiol have opposite effects on podocyte apoptosis
that precedes glomerulosclerosis in female estrogen receptor knockout mice.
Kidney Int 79: 404–413.
12. Sun J, Langer WJ, Devish K, Lane PH (2006) Compensatory kidney growth in
estrogen receptor-alpha null mice. AmJPhysiol Renal Physiol 290: F319–F323.
13. Gross ML, Adamczak M, Rabe T, Harbi NA, Krtil J, et al. (2004) Beneficial
Effects of Estrogens on Indices of Renal Damage in Uninephrectomized SHRsp
Rats. J Am Soc Nephrol 15: 348–358.
14. Tofovic SP, Dubey R, Salah EM, Jackson EK (2002) 2-Hydroxyestradiol
attenuates renal disease in chronic puromycin aminonucleoside nephropathy.
J Am Soc Nephrol 13: 2737–2747.
15. Mundel P, Shankland SJ (2002) Podocyte biology and response to injury. J Am
Soc Nephrol 13: 3005–3015.
16. Kriz W, Gretz N, Lemley KV (1998) Progression of glomerular diseases: is the
podocyte the culprit? Kidney Int 54: 687–697.
17. Shankland SJ (2006) The podocyte’s response to injury: role in proteinuria and
glomerulosclerosis. Kidney Int 69: 2131–2147.
18. Boland R, Vasconsuelo A, Milanesi L, Ronda AC, de Boland AR (2008) 17beta-
Estradiol signaling in skeletal muscle cells and its relationship to apoptosis.
Steroids 73: 859–863.
19. Klinge CM (2008) Estrogenic control of mitochondrial function and biogenesis.
J Cell Biochem 105: 1342–1351.
20. Bjornstrom L, Sjoberg M (2005) Mechanisms of estrogen receptor signaling:
convergence of genomic and nongenomic actions on target genes. Mol
Endocrinol 19: 833–842.
21. Koh PO (2007) Estradiol prevents the injury-induced decrease of 90 ribosomal
S6 kinase (p90RSK) and Bad phosphorylation. Neurosci Lett 412: 68–72.
22. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, et al. (2001)
Mitogen-activated protein (MAP) kinase pathways: regulation and physiological
functions. Endocr Rev 22: 153–183.
23. Song RX, Barnes CJ, Zhang Z, Bao Y, Kumar R, et al. (2004) The role of Shc
and insulin-like growth factor 1 receptor in mediating the translocation of
estrogen receptor alpha to the plasma membrane. Proceedings of the National
Academy of Sciences of the United States of America 101: 2076–2081.
24. Thomas D, Patterson SD, Bradshaw RA (1995) Src homologous and collagen (Shc)
proteinbindstoF-actinandtranslocatestothecytoskeletonuponnervegrowthfactor
stimulation in PC12 cells. The Journal of biological chemistry 270: 28924–28931.
25. Zhang Z, Kumar R, Santen RJ, Song RX (2004) The role of adapter protein
Shc in estrogen non-genomic action. Steroids 69: 523–529.
26. Inokuchi S, Shirato I, Kobayashi N, Koide H, Tomino Y, et al. (1996) Re-
evaluation of foot process effacement in acute puromycin aminonucleoside
nephrosis. Kidney Int 50: 1278–1287.
Estradiol Protects Podocytes from Apoptosis
PLoS ONE | www.plosone.org 9 November 2011 | Volume 6 | Issue 11 | e2745727. Ly JD, Grubb DR, Lawen A (2003) The mitochondrial membrane potential
(deltapsi(m)) in apoptosis; an update. Apoptosis 8: 115–128.
28. Arnold S, Beyer C (2009) Neuroprotection by estrogen in the brain: the
mitochondrial compartment as presumed therapeutic target. J Neurochem 110:
1–11.
29. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME (1995) Opposing
effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270:
1326–1331.
30. Schiffer M, Bitzer M, Roberts IS, Kopp JB, ten Dijke P, et al. (2001) Apoptosis
in podocytes induced by TGF-beta and Smad7. J Clin Invest 108: 807–816.
31. Birch Nielsen C, Krag S, R OS, Flyvbjerg A, Nyengaard J, et al. (2004)
Transforming growth factor beta1-induced glomerulopathy is prevented by
17beta-estradiol supplementation. Virchows Arch 444: 561–566.
32. Lovegrove AS, Sun J, Gould KA, Lubahn DB, Korach KS, et al. (2004)
Estrogen receptor alpha-mediated events promote sex-specific diabetic glomer-
ular hypertrophy. Am J Physiol Renal Physiol 287: F586–591.
33. Couse JF, Yates MM, Walker VR, Korach KS (2003) Characterization of the
hypothalamic-pituitary-gonadal axis in estrogen receptor (ER) Null mice reveals
hypergonadism and endocrine sex reversal in females lacking ERalpha but not
ERbeta. Mol Endocrinol 17: 1039–1053.
34. Pare G, Krust A, Karas RH, Dupont S, Aronovitz M, et al. (2002) Estrogen
receptor-alpha mediates the protective effects of estrogen against vascular injury.
Circ Res 90: 1087–1092.
35. Nitsch W, Thein K (1955) [Therapy of the nephrotic syndrome with estradiol.].
Ther Ggw 94: 364–366.
36. Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, et al. (2010)
Postmenopausal Hormone Therapy: An Endocrine Society Scientific Statement.
J Clin Endocrinol Metab 95: s1–s66.
37. Ahmed SB, Culleton BF, Tonelli M, Klarenbach SW, Macrae JM, et al. (2008)
Oral estrogen therapy in postmenopausal women is associated with loss of
kidney function. Kidney Int 74: 370–376.
38. Meng X, Dai X, Liao TD, D’Ambrosio M, Wang F, et al. (2011) Dose-
dependent toxic effects of high-dose estrogen on renal and cardiac injury in
surgically postmenopausal mice. Life Sci 88: 178–186.
39. Schopick EL, Fisher ND, Lin J, Forman JP, Curhan GC (2009) Post-menopausal
hormone use and albuminuria. Nephrol Dial Transplant 24: 3739–3744.
40. Mundel P, Reiser J, Zuniga Mejia BA, Pavenstadt H, Davidson GR, et al. (1997)
Rearrangements of the cytoskeleton and cell contacts induce process formation
during differentiation of conditionally immortalized mouse podocyte cell lines.
Exp Cell Res 236: 248–258.
41. Aulmann S, Adler N, Rom J, Helmchen B, Schirmacher P, et al. (2006) c-myc
amplifications in primary breast carcinomas and their local recurrences. J Clin
Pathol 59: 424–428.
42. Distelmaier F, Koopman WJ, Testa ER, de Jong AS, Swarts HG, et al. (2008)
Life cell quantification of mitochondrial membrane potential at the single
organelle level. Cytometry A 73: 129–138.
43. Dupont S, Krust A, Gansmuller A, Dierich A, Chambon P, et al. (2000) Effect of
single and compound knockouts of estrogen receptors alpha (ERalpha) and beta
(ERbeta) on mouse reproductive phenotypes. Development 127: 4277–4291.
44. Irzyniec T, Mall G, Greber D, Ritz E (1992) Beneficial effect of nifedipine and
moxonidine on glomerulosclerosis in spontaneously hypertensive rats. A
micromorphometric study. Am J Hypertens 5: 437–443.
45. El Nahas AM, Bassett AH, Cope GH, Le Carpentier JE (1991) Role of growth
hormone in the development of experimental renal scarring. Kidney Int 40:
29–34.
46. Amann K, Nichols C, Tornig J, Schwarz U, Zeier M, et al. (1996) Effect of
ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte
structure in experimental renal failure. Nephrol Dial Transplant 11: 1003–1011.
47. Guo G, Morrissey J, McCracken R, Tolley T, Liapis H, et al. (2001)
Contributions of angiotensin II and tumor necrosis factor-alpha to the
development of renal fibrosis. Am J Physiol Renal Physiol 280: F777–785.
48. Amann K, Koch A, Hofstetter J, Gross ML, Haas C, et al. (2001)
Glomerulosclerosis and progression: effect of subantihypertensive doses of alpha
and beta blockers. Kidney Int 60: 1309–1323.
49. Schwarz U, Amann K, Orth SR, Simonaviciene A, Wessels S, et al. (1998) Effect
of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized
rats. Kidney Int 53: 1696–1705.
Estradiol Protects Podocytes from Apoptosis
PLoS ONE | www.plosone.org 10 November 2011 | Volume 6 | Issue 11 | e27457